Tri Locum Partners’s United Therapeutics UTHR Stock Holding History

Tri Locum Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.7M	Sell	70,370 -50,551	-42%	-$25.2M	5.86%	9
2025 Q4	$58.9M	Sell	120,921 -1,266	-1%	-$590K	7.65%	4
2025 Q3	$51.2M	Buy	+122,187	New	+$41.1M	11.77%	2
2024 Q4	–	Sell	-54,926	Closed	-$19.7M	–	32
2024 Q3	$19.7M	Buy	54,926 +4,826	+10%	+$1.63M	4.72%	9
2024 Q2	$16M	Buy	+50,100	New	+$13.3M	4.04%	14
2022 Q1	–	Sell	-45,904	Closed	-$9.92M	–	49
2021 Q4	$9.92M	Buy	45,904 +13,053	+40%	+$2.56M	3.91%	11
2021 Q3	$6.06M	Buy	+32,851	New	+$6.47M	2.41%	17

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Tri Locum Partners's UTHR Position: Q1 2026 in Review

Tri Locum Partners reduced its United Therapeutics (UTHR) stake by 42% in Q1 2026, selling an estimated $25.2M and leaving 70,370 shares worth $41.7M. The position accounts for 5.86% of the portfolio, ranked #9.

Tri Locum Partners first reported a position in UTHR in Q3 2021 and has held it in 7 quarters since. The position peaked at $58.9M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Tri Locum Partners held 70,370 shares of United Therapeutics worth $41.7M as of Q1 2026.
Tri Locum Partners sold 50,551 United Therapeutics shares in Q1 2026, an estimated $25.2M.
United Therapeutics made up 5.86% of Tri Locum Partners's portfolio in Q1 2026, its #9 holding.
Tri Locum Partners first reported a position in United Therapeutics in Q3 2021 and has held it in 7 quarters since.
Tri Locum Partners's United Therapeutics position peaked at $58.9M in Q4 2025.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.